Maryland

Global health R&D delivers for Maryland

Click here to select a new state

Select a new state

US government investment in global health R&D has delivered

$8.7 billion

to Maryland research institutions

105,600+ new jobs

for Maryland

Maryland's top USG-funded global health R&D institutions

Johns Hopkins University (including the Bloomberg School of Public Health)

$819.1 million

Leidos Biomedical Research

$813.9 million

University of Maryland, Baltimore (including Center for Vaccine Development and Global Health)

$326.2 million

Advanced Bioscience Laboratory

$315.6 million

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

$313.8 million

US Army Fort Detrick (self-funding or other agency transfers)

$192.1 million

Technical Resources International Inc. (TRI)

$166.7 million

Westat Inc.

$125.6 million

Sanaria Inc.

$123.4 million

International Partnership for Microbicides*

$103 million

Social & Scientific Systems Inc.*

$92.7 million

Profectus Biosciences Inc.*

$56.5 million

Abviro LLC

$36.9 million

Quality Biological Inc.

$36 million

University of Maryland, College Park

$32.1 million

BIOQUAL

$31.5 million

Akonni Biosystems Inc.

$29.1 million

Imquest BioSciences

$24.7 million

Biomedical Research Institute

$24.1 million

Ellume

$23.2 million

Unither Virology

$22.1 million

EMMES Corporation

$20 million

Integrated BioTherapeutics Inc.

$19.4 million

Emergent Biosolutions

$16 million

Foundation for the National Institutes of Health

$11.3 million

Axle Informatics

$10.1 million

Zalgen Labs

$9.3 million

US Uniformed Services University of the Health Sciences (self-funding or other agency transfers)

$9.1 million

Medical Science & Computing LLC (MSC)

$8.9 million

DynPort Vaccine Company

$8.7 million

Sequella

$7.4 million

Protein Potential

$6.4 million

Accelevir Diagnostics LLC

$5.8 million

Digital Infuzion

$5.8 million

Intralytix

$4.9 million

Gryphon Scientific

$4.6 million

MacroGenics

$4.5 million

Radix Pharmaceuticals Inc.*

$4.5 million

Scanogen

$3.8 million

Undisclosed MD-based industry recipient

$3.5 million

US Food and Drug Administration (self-funding or other agency transfers)

$3.4 million

Aeras*

$3.1 million

Plantvax

$3 million

VLP Therapeutics

$2.9 million

Novel Microdevices Inc. (formerly Novel Dx)

$2.8 million

Tengen Biomedical

$2.8 million

PathoVax

$2.7 million

University of Maryland Biotechnology Institute*

$2.3 million

GenVec*

$2 million

Meso Scale Diagnostics LLC

$1.7 million

Precision Bioservices

$1.2 million

US Health Resources & Services Administration (self-funding or other agency transfers)

$1.1 million

DFH Pharma

$1 million

Codex Biosolutions Inc.

$965 thousand

Rakta Therapeutics

$862 thousand

Definitive Biotechnologies LLC

$810 thousand

Lieber Institute for Brain Development

$758 thousand

EMINENT Services Corporation

$739 thousand

Information Management Services Inc. (IMS)

$721 thousand

Biofactura Inc.

$719 thousand

Imec Group LLC

$687 thousand

ReProtect*

$682 thousand

Cascade Therapeutics

$539 thousand

Sigmovir Biosystems

$539 thousand

Lumina Corps (formerly NOVA Research Company)

$536 thousand

Towson University

$506 thousand

LTS Corporation*

$469 thousand

Bacilligen Inc.*

$341 thousand

Council Rock Consulting

$338 thousand

SD Nanosciences*

$313 thousand

Infratrac Inc.

$304 thousand

Rise Therapeutics

$283 thousand

CosmosID Inc.

$278 thousand

Medigen Inc.

$266 thousand

Prompt Diagnostics LLC

$259 thousand

Kennedy Krieger Institute (including Hugo W. Moser Research Institute)

$234 thousand

CAMRIS International

$216 thousand

Zeteo Tech

$167 thousand

Celadon Laboratories Inc.*

$141 thousand

TA Management Solutions

$133 thousand

Parklawn North Lot LLC

$125 thousand

Tetracore

$105 thousand

Tilt-Up Construction Inc.

$91 thousand

MedStar Health Research Institute

$85 thousand

FCN Inc.

$73 thousand

Advanced Automation Technologies

$69 thousand

Ripple Effect Communications Inc.

$62 thousand

Hememics Biotechnologies Inc.

$28 thousand

Communications Electronics Inc.

$21 thousand

Global Solutions Network Inc.

$20 thousand

US National Institutes of Health (self-funding or other agency transfers)

$4.8 billion

Maryland's top areas of global health R&D by USG funding

12.2%

COVID-19

2.2%

Diarrheal diseases

5.9%

Flioviral diseases (including Ebola, Marburg)

47%

HIV/AIDS

12%

Malaria

4.4%

Neglected tropical diseases

Buruli ulcer

Dengue

Helminth infections (Worms & Flukes)

Kinetoplastid diseases

Leprosy

Trachoma

5.9%

Tuberculosis

10.3%

Other

Arenaviral hemorrhagic fevers (including Lassa fever)

Bacterial pneumonia & meningitis

Bunyaviral diseases (including CCHF, RVF, SFTS)

Chikungunya

Cryptococcal meningitis

Emergent non-polio enteroviruses (including EV71, D68)

Henipaviral diseases (including Nipah)

Hepatitis B

Hepatitis C

Histoplasmosis

Mpox

Multi-disease/health area R&D

Other coronaviruses (including MERS, SARS)

Reproductive health

Salmonella infections

Zika

Neglected and emerging diseases in Maryland

Chikungunya cases

Dengue cases

HIV diagnoses

4126

Malaria cases

222

Mpox cases

147

Tuberculosis cases

1076

Global health R&D at work in Maryland

University of Maryland’s Center for Vaccine Development and Global Health is at the forefront of advancing next-generation vaccines for malaria. The center led clinical trials of a promised whole parasite vaccine candidate developed by the Maryland-based biotech Sanaria. It is also conducting the first-in-human studies of an mRNA-based malaria vaccine developed by BioNTech—the maker of the Pfizer/BioNTech COVID-19 vaccine—which also runs a facility in the state of Maryland. Vaccines are an important tool in the ongoing fight against malaria. While vaccines for this age-old disease have recently become available, next-generation versions are needed that have fewer doses and improved efficacy.

Footnotes

Methodology
US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
*Organization appears to be closed/out of business.
Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
Case study photo: Maryland GovPics/JayBaker